anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Socket preservation is completed at the time of extraction. After removal of the tooth, the gum is elevated away from the bone, the socket is thoroughly cleansed, the socket is packed with the SBG and the wound closed. A healing time between 3 to 9 months is .
The invention belongs to the technical field of medical bioengineering. SIRPalpha is a member of an inhibitory receptor protein family. The immunoloregulation effect of a dendritic cell (DC) has been reported, the SIRPalpha can inhibit the DC maturation induced by LPS and the IL-12 secretion of the matured DC, the SIRPalpha on the surface of the DC can bidirectionally and negatively regulate the function of a T cell and the DC through the action of the SIRPalpha with a ligand CD47 on the T cell. No application of the SIRPalpha in the preparation of medicines for preventing and treating allergic diseases is reported in literatures at present. The invention aims to provide a new purpose of the SIRPalpha. SIRPalpha gene is cloned, a plasmid is constructed, and overexpression or the SIRPalpha expression interference can be carried out in the invention. The application of the SIRPalpha in the preparation of the medicines for preventing and treating the allergic diseases is provided in the invention.
Patients with newly diagnosed PTCL were treated with a combination of Duvelisib and Chidamide. The dose of Duvelisib was 25mg twice a day. Every 4 weeks (28 days) is a cycle with a total of 2 cycles.
A method for remotely witnessing a medical workflow is provided. The method includes authenticating a clinician at a witnessing device. The method also includes receiving, at the witnessing device, a request to perform a medical workflow. The method further includes determining, at the witnessing device and based at least in part on the medical workflow, that a witness is required to observe the medical workflow. The method also includes initiating, at a witnessing client remotely coupled with the witnessing device, a witnessing session, wherein the witnessing client allows a witness to remotely observe the medical workflow. The method also includes enabling, in response to at least the initiation of the witnessing session, completion of the medical workflow. Related systems and articles of manufacture, including apparatuses and computer program products, are also disclosed.
Oxygen sensors enable cells to adapt to limited oxygen availability (hypoxia), affecting various cellular and tissue responses. Prolyl-4-hydroxylase domain 1-3 (PHD1-3; also called Egln1-3, HIF-P4H 1-3, HIF-PH 1-3) proteins belong to the Fe2+- and 2-oxoglutarate-dependent dioxygenase superfamily and utilise molecular oxygen (O2) alongside 2-oxoglutarate as co-substrate to hydroxylate two proline residues of α subunits of the dimeric hypoxia inducible factor (HIF) transcription factor. PHD1-3-mediated hydroxylation of HIF-α leads to its degradation and inactivation. Recently, various PHD inhibitors (PHI) have entered the clinics for treatment of renal anaemia. Pre-clinical analyses indicate that PHI treatment may also be beneficial in numerous other hypoxia-associated diseases. Nonetheless, the underlying molecular mechanisms of the observed protective effects of PHIs are only partly understood, currently hindering their translation into the clinics. Moreover, the PHI-mediated increase of Epo levels is not beneficial in all hypoxia-associated diseases and PHD-selective inhibition may be advantageous. Here, we summarise the current knowledge about the relevance and function of each of the three PHD isoforms in vivo, based on the deletion or RNA interference-mediated knockdown of each single corresponding gene in rodents. This information is crucial for our understanding of the physiological relevance and function of the PHDs as well as for elucidating their individual impact on hypoxia-associated diseases. Furthermore, this knowledge highlights which diseases may best be targeted by PHD isoform-selective inhibitors in case such pharmacologic substances become available.
All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
PURPOSE: Postoperative nausea and vomiting (PONV) frequently occur in patients after surgery. In this study, the authors investigated whether perioperative S-ketamine infusion could decrease the incidence of PONV in patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy.
PATIENTS AND METHODS: This prospective, randomized, double-blinded, controlled study was conducted a total of 420 patients from September 2021 to May 2023 at Xuzhou Central Hospital in China, who underwent elective VATS lobectomy under general anesthesia with tracheal intubation. The patients were randomly assigned to either the S-ketamine group or the control group. The S-ketamine group received a bolus injection of 0.5 mg/kg S-ketamine and an intraoperative continuous infusion of S-ketamine at a rate of 0.25 mg/kg/h. The control group received an equivalent volume of saline. All patients were equipped with patient-controlled intravenous analgesia (PCIA), with a continuous infusion rate of 0.03 mg/kg/h S-ketamine in the S-ketamine group or 0.03 μg/kg/h sufentanil in the control group. The primary outcome was the incidence of PONV. Secondary outcomes included perioperative opioid consumption, hemodynamics, postoperative pain, and adverse events.
RESULTS: The incidence of PONV in the S-ketamine group (9.7%) was significantly lower than in the control group (30.5%). Analysis of perioperative opioid usage revealed that remifentanil usage was 40.0% lower in the S-ketamine group compared to the control group (1414.8 μg vs 2358.2 μg), while sufentanil consumption was 75.2% lower (33.1 μg vs 133.6 μg). The S-ketamine group demonstrated better maintenance of hemodynamic stability. Additionally, the visual analogue scale (VAS) scores on postoperative day 1 (POD-1) and postoperative day 3 (POD-3) were significantly lower in the S-ketamine group. Finally, no statistically significant difference in other postoperative adverse reactions was observed between the two groups.
CONCLUSION: The results of this trial indicate that perioperative S-ketamine infusion can effectively reduce the incidence of PONV in patients undergoing VATS lobectomy.
Meropenem for injection is a sterile, pyrogen-free, synthetic, carbapenem antibacterial drug for intravenous administration. Meropenem is (4R,5S,6S)-3- [[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate. Its empirical formula is C17H25N3O5S•3H2O with a molecular weight of 437.52.

Its structural formula is:

Meropenem for injection is a white to pale yellow crystalline powder containing meropenem trihydrate and sodium carbonate. The constituted solution varies from colorless to yellow depending on the concentration. The pH of freshly constituted solutions is between 7.3 and 8.3. Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether. 

Meropenem for Injection USP and Sodium Chloride Injection USP is supplied as a sterile, nonpyrogenic, single-dose packaged combination of meropenem (drug chamber) and 50 mL of sodium chloride (diluent) in the DUPLEX® sterile container. When reconstituted as instructed, each 1 gram Meropenem for injection in the DUPLEX® Container will deliver 1 gram of meropenem and a total sodium content of 290.2 mg (12.6 mEq). Each 500 mg Meropenem for injection in the DUPLEX® Container will deliver 500 mg of meropenem and a total sodium content of 245.1 mg (10.7 mEq) [see Dosage and Administration (2.4)]. The osmolality of the reconstituted solution of Meropenem for Injection USP and Sodium Chloride Injection USP is approximately 356 mOsmol/kg for the 500 mg dose and approximately 417 mOsmol/kg for the 1 gram dose.

The DUPLEX® Container is a flexible dual chamber container. After removing the peelable foil strip, activating the seals, and thoroughly mixing, the reconstituted drug product is hyperosmotic and is intended for single intravenous use. The product (diluent and drug) contact layer is a mixture of thermoplastic rubber and a polypropylene ethylene copolymer that contains no plasticizers.

Not made with natural rubber latex, PVC or Di(2-ethylhexyl)phthalate (DEHP).
The biologically active composition has vegetable origin of Prunella vulgaris (common self-heal), consisting of two herbal components and the biologically active substances contained in them in the original combination: (i) stalk of common self-heal (Prunellae herba) (ii) spike of common self-heal (Prunellae spica). Each of the components is derived from different morphological parts of the plant, under specific collection conditions and method of primary processing. The biologically active composition has a pronounced antioxidant activity, anti-inflammatory effect, antibacterial and antiviral action, with antioxidant, supportive and protective function on the skin. According to the utility model, it can be used in the production of therapeutic and prophylactic herbal products, food supplements, herbal teas, instant herbal teas, products in the food industry and in cosmetic products. It is suitable in the initial phase of inflammatory diseases of various origins. It helps the body in conditions of reduced immunity. It is supplement in the diet for healthy nutrition with a beneficial effect on human health. Suitable for daily use.
Salmonella enterica is one of the most important zoonotic pathogens causing foodborne gastroenteritis worldwide. Outer membrane vesicles (OMVs) are lipid-bilayer vesicles produced by Gram-negative bacteria, which contain biologically active components. We hypothesized that OMVs are an important weapon of S. enterica to initiate enteric diseases pathologies. In this study, the effects of S. enterica OMVs (SeOMVs) on intestinal microbiota and intestinal barrier function were investigated. In vitro fecal culture experiments showed that alpha diversity indexes and microbiota composition were altered by SeOMV supplementation. SeOMV supplementation showed an increase of pH, a decrease of OD630 and total short chain fatty acid (SCFA) concentrations. In vitro IPEC-J2 cells culture experiments showed that SeOMV supplementation did not affect the IPEC-J2 cell viability and the indicated genes expression. In vivo experiments in mice showed that SeOMVs had adverse effects on average daily gain (p < 0.05) and feed:gain ratio (p < 0.05), and had a tendency to decrease the final body weight (p = 0.073) in mice. SeOMV administration decreased serum interleukin-10 level (p < 0.05), decreased the relative abundance of bacteria belonging to the genera BacC-u-018 and Akkermansia (p < 0.05). Furthermore, SeOMV administration damaged the ileum mucosa (p < 0.05). These findings suggest that SeOMVs play an important role in the activation of intestinal inflammatory response induced by S. enterica, and downregulation of SCFA-producing bacteria is a possible mechanism.
Preparation of the Technetium Tc99m Bicisate from the NEUROLITE®, Kit for the Preparation of Technetium Tc99m Bicisate Injection, is done by the following aseptic procedure:

  1. Prior to adding the Sodium Pertechnetate Tc99m Injection to vial B (the liquid vial), write the estimated activity, date, and time of preparation in the space provided on the vial label. Then tear off a radiation symbol and attach it to the neck of the vial.
  2. Waterproof gloves should be worn during the preparation procedure. Remove the plastic disc from both vials and swab the top of each vial closure with alcohol to disinfect the surface.
  3. Place vial B in a suitable radiation shield appropriately labeled with date, time of preparation, volume and activity.
  4. With a sterile shielded syringe, aseptically add 3.70 GBq (100 mCi) sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection, in approximately 2.0 mL, to vial B. Without withdrawing the needle, remove an equal volume of air to maintain pressure within the vial.
  5. With a sterile syringe, rapidly inject 3.0 mL of Sodium Chloride Injection (0.9%) into vial A (the lyophilized vial) to dissolve the contents. Without withdrawing the needle, remove an equal volume of air to maintain pressure within the vial. Shake the contents of the vial for a few seconds.
  6. With another sterile syringe, immediately (within 30 seconds) withdraw 1.0 mL of vial A and inject it into vial B. Discard vial A immediately.
  7. Swirl the contents of the vial B for a few seconds, and allow this mixture to stand for thirty (30) minutes at room temperature.
  8. Examine the vial contents for particulates and discoloration prior to patient administration. If particulate matter and/or discoloration are seen, DO NOT USE.
  9. Assay the reaction vial using a suitable radioactivity calibration system. Record the Technetium Tc99m concentration, total volume, assay time and date, expiration time and lot number on the vial shield label and affix the label to the shield.
  10. Store the reaction vial containing the Technetium Tc99m Bicisate at controlled room temperature until use; at such time the product should be aseptically withdrawn. The vial contains no preservative.



Note: Adherence to the above product reconstitution instructions is recommended.

Product should be used within 6 hours of preparation.
A computer-implemented method for calculating estimated risk of serious gastrointestinal (GI) hospitalization of a patient taking nonsteroidal anti-inflammatory drugs includes the steps of obtaining patient values of a plurality of predictive factors, calculating an estimated risk from the patient values, and displaying the estimated risk, preferably on a monitor. The predictive factors may be age, global health status, proportion of time taking prednisone, occurrence of a previous GI side effect, and occurrence of a previous GI hospitalization. Preferably, the estimated risk is calculated from a Cox proportional hazard model, derived from a database of arthritis patients, using either continuous or categorical variables. The continuous model applies a standard Cox model to the predictive factors. The categorical model divides each predictive factor into categories, and assigns a point value to each predictive factor. The point values are added to derive a point total, which is converted to an estimated risk using a predetermined correlation between point total and estimated risk.
The present study included 62 patients (15 male and 47 females, aged 12 to 60 years). The initial cervical dentin hypersensitivity was checked throughout a thermal test (air blast). The 434 teeth included were that with a score ≥5 in a numerical scale rating of pain. Teeth were randomly assigned according quadrants (split mouth design) - 216 were allocated to LILT group and 218 for the Super Bonder® group. Thermal tests with a tetrafluoroethane spray (Endo-Ice®) and air blast were performed and considered as baseline. Pain parameters were recorded using a numerical scale rating with 24 hours, 30, 90 and 180 days after the interventions. Quality of life of the patients was also assessed with the use of OHIP-14 at baseline and after 180 days.
Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
a large-scale unmanned hospital system using artificial intelligence; the method comprises the following steps: intelligent terminal, communication device, peripheral equipment, memory cell, intelligent unit, main control unit. The disease-watching software puts forward various types of inquiry requirements from the inquiry question set, and the user clicks a fixed answer to answer or carries out additional user answers; the user demands, and the doctor software answers or executes the demands; the medical software obtains disease signs. The doctor software compares the inquiry conclusion with the case parameters of the same subject in the case database, and the doctor software respectively gives corresponding doctor reports. The prescription software compares and identifies the parameters in the diagnosis report with the parameters in the prescription source, and issues a corresponding treatment prescription or a health care prescription. The system is initiated by an unmanned hospital to diagnose diseases and treat the diseases timely and comprehensively, and subverts the passive and other patients of the contemporary medicine to get ill and the emergency medical treatment of the patients with serious diseases. The development of unmanned hospitals is mature and the replacement of most of solid hospitals is a great trend of the times.
Eligible participants will receive VH4524184 under fasted condition in Treatment Period 1 followed by VH4524184 under fed condition in Treatment Period 2 during Cohort 10 (Part 3) of the study. Treatment Periods will be separated by a washout period.
Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
New medicaments for use in combatting Hg, Pb or Cd poisoning comprise as active agent (I) dimercaptosuccinic acid or its non-toxic salts, eps. its alkali or alkaline earth metal salts or its salts with Et2NH or glucamine. (I) is used in unit doses of 100-1000 mg, at 1-5 g/day. Hg, which accumulates as CH3HG in the kidneys, liver and brain, is efficiently eliminated from the body, as are Pb and Cd. Administration may be by oral or parenteral routes. The compsn. may be used to prevent accumulation of Hg, Pb or Cd in persons exposed to them in their work.
Systemic lupus erythematosus (SLE) predominantly affects child-bearing women, leading to an elevated risk of maternal and fetal complications and adverse pregnancy outcomes. Since some medications can cross the placental barrier that persist a threat to both mother and fetus, the risk-benefit ratio of SLE medications should be taken into consideration during pregnancy. Calcineurin inhibitor (CNI), mainly including cyclosporin A, tacrolimus, and voclosporin, is a category of immunosuppressive agents that inhibit calcium/calmodulin-dependent phosphatase calcineurin to block T cell activation. Based on the current clinical evidence, CNI is an alternative in pregnant SLE patients with persistent disease activity (especially lupus nephritis patients) and non-responders to azathioprine. However, there is no comprehensive review that summarizes the efficacy and safety profile of CNI for SLE management during pregnancy. This review presents a summary on the utilization of CNI for SLE management during pregnancy, including the mechanism of action, gestational amelioration of lupus flare, and the balance of maternal benefit-fetal risk, which may provide more references for the management of SLE pregnancies.
PROBLEM TO BE SOLVED: To provide a transdermal medical device that comprises an active agent and reduces the incidence of infection.SOLUTION: A transdermal medical device includes a mesh having at least one bioresorbable polymer coating. The coating comprises at least one active agent which is eluted over time. The device at least partially covers at least a portion of an implanted transdermal medical device. Preferably the bioresorbable polymer coating is a tyrosine-derived polyesteramide. Preferably the active agent is an antimicrobial agent, an anesthetic, a procoagulant agent, or an anti-inflammatory agent. Preferably the antimicrobial agent is the one selected from the group consisting of antibiotics, antiseptics, and disinfectants. Preferably the antibiotic is the one selected from the group consisting of tetracyclines, penicillins, macrolides, rifampin and combinations thereof.SELECTED DRAWING: None
After the first evaluation, the training group will be given Schroth exercise training for 12 weeks, 7 days a week, for 60 minutes. This group will be given Schroth exercises under the supervision of a physiotherapist for 2 days in our unit, while home-based Schroth exercise training will be given on other days of the week.
INTRODUCTION: cervical cancer is primarily driven by high-risk human papillomavirus infections. It is a leading cause of cancer-related deaths among women globally. The emergence of immunotherapeutic approaches, particularly programmed death ligand-1 (PD-L1) inhibitors, has shown promise in various cancers. This study aims to investigate the correlation between PD-L1 expression and HPV status in cervical carcinoma samples from a Nigerian tertiary hospital.
METHODS: the study was conducted in the Department of Pathology of our hospital. The study materials were 101 cases of archival formalin-fixed paraffin-embedded (FFPE) tissue blocks that met the study criteria recruited retrospectively from January 2012 to December 2016. Immunohistochemistry for PD-L1 was done and real time PCR for HPV DNA was done using CFX96. The data were then analyzed using SPSS version 23. P < 0.05 was considered significant.
RESULTS: high-risk HPV detection rate was 51%. The two most common genotypes were HPV 16 (84.3%) and HPV 35 (17.6%). The predominant infections were single genotypes occurring in 80.4% of the cases. There was no correlation of HPV status with PD-L1, histological grade or type of cervical carcinoma. High-risk HPV did not show any distribution pattern with age groups of patients.
CONCLUSION: human papillomavirus 16 is the most predominant cause of cervical carcinoma. There are some environmental variations in the frequency of other genotypes with HPV 35 being relatively more common than HPV 18 in this study. Programmed death ligand-1 was positive in 47% of the cases but did not show any correlation with the HPV infection status.
Patients receive CBM588 PO BID on days 1-21, nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles. Patients then receive CBM588 PO BID on days 1-28 and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, bone scan and blood sample collection throughout the study. Patients may optionally undergo MRI on study.
FIELD: biotechnology. SUBSTANCE: method involves preparing inoculum material and industrial culturing the strain Brucella abortus 19 in liquid nutrient medium containing Hottinger's broth, glycerol, glucose, NaCl, yeast autolysate and water. Culturing is carried out under submerged conditions for 19-21 h at regulation of partial pressure of oxygen dissolved in cultural fluid for the all culturing process. After addition of inoculum material the levels of 20-25 pO 2 , 40-45 pO 2  and 30-35 pO 2  are adjusted from 1 to 6 h, from 6 to 16-18 h and then from 16-18 to 19-21 h, respectively. Grown bacterial cells are separated and concentrated by ultrafiltration on fibers with retention limit 15-50 kDa, inactivated by heating, stained with rose Bengal dye, resuspended in buffer diluting agent and the end product is standardized. Invention can be used for industrial production of preparations for diagnosis of brucellosis. EFFECT: simplified technology, decreased time for preparing color brucellosis antigen for rose Bengal specimen, improved quality. 3 ex